- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 -

- Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in accordance with the study protocol -

- Company expects to provide a further update following completion of the Safety Monitoring Committee review –

HUNTSVILLE, Ala., July 23, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the completion of enrollment and dosing in Cohort 1 of its ongoing Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson’s disease.

All eight patients in Cohort 1 have now been dosed across clinical sites in the United States and Australia. The milestone was achieved ahead of the Company’s previously disclosed guidance to complete Cohort 1 enrollment and dosing by the end of the third quarter of 2026.